Abstract Search

ea0089c3 | Clinical – Chemo/SSA/Biologics | NANETS2022

Real World Analysis of Long-Acting Somatostatin Analog (LA-SSA) Treatment and Dose Escalation Among Patients with Neuroendocrine Tumors (NET)

Clarke, MD, MS Callisia N. , Cockrum, BSci, PharmD, RPh Paul , Beveridge, MSc, PhD Thomas J.R. , Jerry, MS Michelle , McMorrow, BS Donna , Thu Tran, PharmD Anh , Phan, MD Alexandria T.

Background: LA-SSA therapy, including octreotide long-acting release (LAR) and lanreotide depot (LAN), is recommended as first-line therapy for treatment of unresectable or metastatic NETs. Understanding treatment sequencing and dosing patterns of LA-SSAs is essential for clinical decision-making to provide value-based management of NET for both the patients and healthcare system. This study describes treatment patterns of LA-SSA therapy among privately insured patients with N...

0 shares

Endocrine Abstracts

Real World Analysis of Long-Acting Somatostatin Analog (LA-SSA) Treatment and Dose Escalation Among Patients with Neuroendocrine Tumors (NET)

BiosciAbstracts